跳至主要内容
临床试验/NCT00361868
NCT00361868终止3 期

A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia

Solvay Pharmaceuticals70 个研究点 分布在 6 个国家目标入组 88 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
88
试验地点
70
主要终点
HbA1c/TG

研究概览

简要总结

Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on glycemic control is not inferior to that of rosiglitazone and the efficacy of FC of fenofibrate and metformin on triglyceride control is superior to that of rosiglitazone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with Type 2 diabetes mellitus and dyslipidemia inadequately controlled with lifestyle modifications.

排除标准

  • Type 1 diabetes.

研究组 & 干预措施

1

Experimental

干预措施: fenofibrate (F) + metformin (M) hydrochloride fixed combination (Drug)

2

Active Comparator

干预措施: Rosiglitazone (Drug)

结局指标

主要结局

HbA1c/TG

时间窗: 24 weeks

次要结局

  • Lipid and glycemic parameters.(24 weeks)

研究者

申办方类型
Industry

研究点 (70)

Loading locations...

相似试验